Antibody-membrane switch (AMS) technology for facile cell line development.

Area of Science:

• Biotechnology
• Molecular Biology
• Biopharmaceutical Manufacturing

Background:

• Therapeutic antibody development relies heavily on high-productivity cell lines, but current methods face challenges.
• Conventional cell line development often uses gene amplification (e.g., DHFR, GS) which can lead to clonal instability during manufacturing.
• Achieving stable, high-yield cell lines is critical for efficient and cost-effective biopharmaceutical production.

Purpose of the Study:

• To introduce a novel cell line development technology, Antibody-Membrane Switch (AMS), that overcomes limitations of traditional methods.
• To demonstrate a FACS-based, high-throughput approach for isolating high-producing cells without relying on gene amplification.
• To enable rapid and efficient development of stable, high-yield antibody-producing cell lines.

Main Methods:

• Antibody-Membrane Switch (AMS) technology utilizes cell-surface antibody display for Fluorescence-Activated Cell Sorting (FACS).
• Alternative splicing and DNA recombination control the switch between membrane-bound and secreted antibody expression.
• High-producing cells are isolated via FACS, and the membrane-anchoring domain is subsequently removed using DNA recombinase.

Main Results:

• AMS technology successfully applied to multiple antibody cell line development projects, with timelines of 2-3 months.
• Isolated top production cell lines achieved high specific productivity (40-60 pg/cell/day).
• Resulting production titers reached 2-4 g/l in 10-day batch cultures.

Conclusions:

• AMS technology offers a novel, efficient, and rapid method for developing stable, high-producing antibody cell lines.
• This FACS-based approach bypasses gene amplification, mitigating clonal instability issues in large-scale manufacturing.
• AMS technology significantly advances biopharmaceutical development by improving cell line productivity and stability.